Index RUT
P/E -
EPS (ttm) -6.34
Insider Own 14.46%
Shs Outstand 26.60M
Perf Week -4.59%
Market Cap 1.16B
Forward P/E -
EPS next Y -6.82
Insider Trans 1.85%
Shs Float 25.83M
Perf Month 1.85%
Income -170.12M
PEG -
EPS next Q -1.70
Inst Own 87.24%
Short Float 21.80%
Perf Quarter 60.33%
Sales 30.47M
P/S 38.14
EPS this Y -9.89%
Inst Trans 4.80%
Short Ratio 16.98
Perf Half Y 57.38%
Book/sh 0.36
P/B 106.86
EPS next Y -2.06%
ROA -36.02%
Short Interest 5.63M
Perf Year 113.78%
Cash/sh 11.62
P/C 3.31
EPS next 5Y -
ROE -214.89%
52W Range 13.36 - 41.31
Perf YTD 79.65%
Dividend Est. -
P/FCF -
EPS past 5Y -19.45%
ROI -43.96%
52W High -6.85%
Beta -0.28
Dividend TTM -
Quick Ratio 9.09
Sales past 5Y 172.96%
Gross Margin 92.14%
52W Low 188.02%
ATR (14) 2.05
Dividend Ex-Date -
Current Ratio 9.09
EPS Y/Y TTM -22.07%
Oper. Margin -508.81%
RSI (14) 57.34
Volatility 5.68% 4.80%
Employees 117
Debt/Eq 38.35
Sales Y/Y TTM 135.59%
Profit Margin -558.25%
Recom 1.18
Target Price 57.40
Option/Short Yes / Yes
LT Debt/Eq 38.17
EPS Q/Q -13.99%
Payout -
Rel Volume 1.55
Prev Close 37.53
Sales Surprise -51.79%
EPS Surprise -64.30%
Sales Q/Q 217.08%
Earnings Aug 05 AMC
Avg Volume 331.58K
Price 38.48
SMA20 3.74%
SMA50 8.67%
SMA200 47.56%
Trades
Volume 512,942
Change 2.53%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-22-24 Initiated
H.C. Wainwright
Buy
$55
Jul-19-24 Upgrade
JP Morgan
Neutral → Overweight
$29 → $69
Apr-16-24 Initiated
Leerink Partners
Outperform
$47
Apr-11-24 Initiated
Wells Fargo
Overweight
$56
Mar-12-24 Upgrade
Wedbush
Neutral → Outperform
$20 → $34
Feb-26-24 Initiated
BTIG Research
Buy
$55
Feb-21-24 Initiated
Stifel
Buy
$50
Feb-16-24 Initiated
Piper Sandler
Overweight
$80
May-22-23 Upgrade
JP Morgan
Underweight → Neutral
$31 → $30
May-18-23 Initiated
TD Cowen
Outperform
Jan-06-23 Downgrade
Raymond James
Outperform → Mkt Perform
Nov-01-22 Upgrade
Guggenheim
Neutral → Buy
$44
Sep-19-22 Resumed
H.C. Wainwright
Buy
$35
Sep-13-22 Downgrade
Truist
Buy → Hold
$50 → $28
Sep-01-22 Initiated
Raymond James
Outperform
$35
Mar-22-22 Downgrade
Guggenheim
Buy → Neutral
Jun-22-21 Initiated
H.C. Wainwright
Buy
$43
May-21-21 Initiated
UBS
Neutral
$29
Mar-16-21 Upgrade
Truist
Hold → Buy
Mar-09-21 Downgrade
Wedbush
Outperform → Neutral
Show Previous Ratings
Aug-29-24 09:15AM
Aug-23-24 07:26AM
Aug-14-24 04:11PM
(Investor's Business Daily)
-6.35%
10:05AM
(Investor's Business Daily)
05:00AM
09:54PM
Loading…
Aug-05-24 09:54PM
05:55PM
04:15PM
Jul-29-24 10:00AM
Jul-22-24 02:53PM
May-09-24 05:45PM
04:15PM
04:10PM
04:05PM
May-02-24 10:01AM
04:51AM
Loading…
May-01-24 04:51AM
Apr-24-24 09:00AM
Apr-15-24 02:19PM
Apr-12-24 07:00PM
Apr-09-24 02:40PM
Mar-14-24 12:00PM
09:55AM
Mar-11-24 05:30PM
04:15PM
Feb-29-24 09:15AM
Feb-28-24 10:00AM
Feb-22-24 04:00AM
Feb-19-24 05:54AM
Jan-31-24 09:15AM
Jan-12-24 03:02PM
09:55AM
Loading…
Dec-07-23 09:55AM
Nov-27-23 04:15PM
Nov-14-23 09:35AM
Nov-07-23 04:15PM
Nov-04-23 05:41AM
Nov-02-23 04:15PM
Nov-01-23 09:15AM
Oct-11-23 09:15AM
Oct-09-23 08:27AM
08:15AM
08:05AM
08:00AM
Sep-19-23 03:01PM
Sep-18-23 04:15PM
Sep-12-23 09:15AM
Aug-07-23 04:15PM
Jul-31-23 01:34PM
Jul-04-23 06:22AM
May-30-23 04:15PM
May-24-23 06:01AM
May-22-23 01:44AM
May-11-23 05:35PM
04:15PM
May-04-23 09:55AM
May-02-23 09:15AM
Apr-30-23 09:47AM
Apr-27-23 10:02AM
Apr-26-23 10:02AM
Apr-14-23 03:13AM
Apr-06-23 04:15PM
Apr-03-23 07:14AM
Mar-27-23 06:50PM
Mar-01-23 05:45PM
04:05PM
Feb-27-23 04:05PM
Jan-13-23 09:00AM
Jan-05-23 04:05PM
Dec-22-22 09:33AM
Dec-02-22 09:00AM
Nov-21-22 01:56PM
Nov-11-22 05:19AM
Nov-09-22 02:10PM
Nov-08-22 05:55PM
04:05PM
Oct-25-22 06:28AM
Oct-13-22 09:55AM
Oct-06-22 11:02AM
Oct-05-22 11:31AM
09:00AM
Sep-26-22 08:00AM
Sep-19-22 02:02PM
Sep-14-22 06:14AM
Sep-12-22 11:18AM
07:30AM
Sep-02-22 01:41PM
Sep-01-22 09:58AM
Aug-31-22 04:15PM
Aug-10-22 06:28AM
Aug-08-22 05:35PM
04:05PM
Aug-05-22 04:00PM
Jul-08-22 07:22AM
Jun-24-22 06:31AM
Jun-02-22 04:05PM
May-10-22 06:09AM
May-04-22 06:55PM
04:15PM
Apr-28-22 08:48AM
Apr-27-22 04:15PM
Apr-26-22 07:05AM
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Orwin John A Director Sep 15 '24 Option Exercise 0.00 1,300 0 3,335 Sep 17 06:45 PM LOUMEAU ERIC J CHIEF LEGAL OFFICER Sep 16 '24 Option Exercise 14.02 5,000 70,100 13,520 Sep 17 06:44 PM LOUMEAU ERIC J CHIEF LEGAL OFFICER Sep 14 '24 Option Exercise 0.00 6,000 0 10,740 Sep 17 06:44 PM LOUMEAU ERIC J CHIEF LEGAL OFFICER Sep 16 '24 Sale 39.82 8,720 347,270 7,020 Sep 17 06:44 PM LOUMEAU ERIC J CHIEF LEGAL OFFICER Sep 17 '24 Sale 38.41 3,780 145,191 3,240 Sep 17 06:44 PM Lizzul Paul F. Chief Medical Officer Sep 16 '24 Sale 38.93 2,220 86,425 15,398 Sep 17 06:42 PM MULROY DENNIS CHIEF FINANCIAL OFFICER Sep 16 '24 Option Exercise 20.16 10,000 201,600 14,744 Sep 17 06:41 PM MULROY DENNIS CHIEF FINANCIAL OFFICER Sep 16 '24 Sale 39.91 12,220 487,725 4,744 Sep 17 06:41 PM ERIC J LOUMEAU Officer Sep 17 '24 Proposed Sale 38.41 3,780 145,191 Sep 17 04:02 PM DENNIS MULROY Officer Sep 16 '24 Proposed Sale 40.13 10,000 401,300 Sep 16 04:33 PM ERIC J LOUMEAU Officer Sep 16 '24 Proposed Sale 40.13 6,500 260,845 Sep 16 04:22 PM Lizzul Paul F. Chief Medical Officer Aug 14 '24 Option Exercise 18.50 2,000 37,000 13,618 Aug 16 04:09 PM Lizzul Paul F. Chief Medical Officer Aug 14 '24 Sale 40.00 2,000 80,000 11,618 Aug 16 04:09 PM EcoR1 Capital, LLC 10% Owner Aug 14 '24 Buy 36.50 273,972 9,999,978 7,794,996 Aug 16 12:04 PM PAUL F LIZZUL Officer Aug 14 '24 Proposed Sale 40.00 2,000 80,000 Aug 14 04:34 PM Lizzul Paul F. Chief Medical Officer Jul 18 '24 Option Exercise 18.50 1,500 27,750 13,118 Jul 19 08:35 PM Lizzul Paul F. Chief Medical Officer Jul 18 '24 Sale 35.00 1,500 52,500 11,618 Jul 19 08:35 PM RENTON HOLLINGS Director Jul 15 '24 Option Exercise 6.93 10,000 69,300 11,950 Jul 17 04:45 PM RENTON HOLLINGS Director Jul 15 '24 Sale 30.64 10,000 306,422 1,950 Jul 17 04:45 PM FENTON DENNIS M Director Jun 21 '24 Sale 23.17 1,950 45,182 1,950 Jun 24 05:23 PM FENTON DENNIS M Director Jun 15 '24 Option Exercise 0.00 3,900 0 3,900 Jun 18 08:18 PM Marquet Magda Director Jun 15 '24 Option Exercise 0.00 3,900 0 3,900 Jun 18 08:17 PM Schmid John P. Director Jun 15 '24 Option Exercise 0.00 3,900 0 3,900 Jun 18 08:17 PM Ware J. Anthony Director Jun 15 '24 Option Exercise 0.00 3,900 0 7,500 Jun 18 08:16 PM Orwin John A Director Jun 15 '24 Option Exercise 0.00 2,035 0 2,035 Jun 18 08:15 PM RENTON HOLLINGS Director Jun 15 '24 Option Exercise 0.00 3,900 0 3,900 Jun 18 08:15 PM RENTON HOLLINGS Director Jun 18 '24 Sale 23.16 1,950 45,162 1,950 Jun 18 08:15 PM Jain Rita Director Jun 15 '24 Option Exercise 0.00 4,534 0 4,534 Jun 18 08:14 PM MULROY DENNIS CHIEF FINANCIAL OFFICER May 22 '24 Sale 23.72 1,500 35,580 964 May 24 04:12 PM Faga Daniel CEO Mar 22 '24 Sale 22.78 145,940 3,325,185 752,087 Mar 26 08:10 PM Faga Daniel CEO Mar 25 '24 Sale 21.42 3,000 64,268 749,087 Mar 26 08:10 PM LOUMEAU ERIC J CHIEF LEGAL OFFICER Feb 16 '24 Option Exercise 14.02 5,000 70,100 8,240 Feb 21 05:38 PM LOUMEAU ERIC J CHIEF LEGAL OFFICER Feb 16 '24 Sale 25.00 5,000 125,000 3,240 Feb 21 05:38 PM MULROY DENNIS CHIEF FINANCIAL OFFICER Jan 30 '24 Sale 23.63 3,065 72,425 964 Feb 01 05:27 PM Lizzul Paul F. Chief Medical Officer Jan 06 '24 Option Exercise 0.00 6,145 0 12,672 Jan 09 07:08 PM Lizzul Paul F. Chief Medical Officer Jan 08 '24 Sale 21.81 2,554 55,703 10,118 Jan 09 07:08 PM LOUMEAU ERIC J Chief Legal Officer Jan 06 '24 Option Exercise 0.00 5,545 0 5,545 Jan 09 07:07 PM LOUMEAU ERIC J Chief Legal Officer Jan 08 '24 Sale 21.81 2,305 50,272 3,240 Jan 09 07:07 PM MULROY DENNIS Chief Financial Officer Jan 06 '24 Option Exercise 0.00 5,245 0 6,209 Jan 09 07:06 PM MULROY DENNIS Chief Financial Officer Jan 08 '24 Sale 21.81 2,180 47,546 4,029 Jan 09 07:06 PM Faga Daniel CEO Jan 06 '24 Option Exercise 0.00 17,850 0 904,893 Jan 09 07:05 PM Faga Daniel CEO Jan 08 '24 Sale 21.81 6,866 149,747 898,027 Jan 09 07:05 PM LOUMEAU ERIC J Chief Legal Officer Nov 22 '23 Sale 14.19 882 12,516 0 Nov 27 04:03 PM
Index RUT
P/E -
EPS (ttm) -1.52
Insider Own 2.72%
Shs Outstand 70.12M
Perf Week 4.39%
Market Cap 937.51M
Forward P/E -
EPS next Y -1.16
Insider Trans 0.00%
Shs Float 69.67M
Perf Month 17.93%
Income -112.51M
PEG -
EPS next Q -0.40
Inst Own 96.31%
Short Float 6.04%
Perf Quarter 55.65%
Sales 62.71M
P/S 14.95
EPS this Y 35.59%
Inst Trans -0.51%
Short Ratio 6.02
Perf Half Y 22.91%
Book/sh 5.69
P/B 2.30
EPS next Y -4.69%
ROA -20.13%
Short Interest 4.21M
Perf Year 97.14%
Cash/sh 4.61
P/C 2.84
EPS next 5Y 11.00%
ROE -26.32%
52W Range 6.01 - 13.14
Perf YTD 25.99%
Dividend Est. -
P/FCF -
EPS past 5Y -6.52%
ROI -26.57%
52W High -0.38%
Beta 1.19
Dividend TTM -
Quick Ratio 7.01
Sales past 5Y 264.10%
Gross Margin 76.51%
52W Low 117.62%
ATR (14) 0.46
Dividend Ex-Date -
Current Ratio 7.01
EPS Y/Y TTM -154.13%
Oper. Margin -191.47%
RSI (14) 77.12
Volatility 3.75% 3.71%
Employees 277
Debt/Eq 0.05
Sales Y/Y TTM -85.99%
Profit Margin -179.42%
Recom 1.86
Target Price 14.00
Option/Short Yes / Yes
LT Debt/Eq 0.04
EPS Q/Q 35.12%
Payout -
Rel Volume 1.06
Prev Close 13.05
Sales Surprise 61.22%
EPS Surprise -17.37%
Sales Q/Q 174.82%
Earnings Aug 01 AMC
Avg Volume 699.36K
Price 13.09
SMA20 10.07%
SMA50 19.70%
SMA200 29.09%
Trades
Volume 742,271
Change 0.31%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-21-23 Resumed
Wells Fargo
Overweight
$12
Jan-04-23 Reiterated
H.C. Wainwright
Neutral
$10 → $8
Dec-20-22 Upgrade
Jefferies
Hold → Buy
$7.70 → $11
Nov-01-22 Downgrade
H.C. Wainwright
Buy → Neutral
$40 → $8
Oct-21-22 Downgrade
SVB Leerink
Outperform → Mkt Perform
$8
Oct-04-22 Resumed
Wells Fargo
Overweight
$45 → $9
May-05-22 Upgrade
Guggenheim
Neutral → Buy
$14
Mar-15-22 Initiated
Evercore ISI
Outperform
$15
Dec-10-21 Upgrade
SVB Leerink
Mkt Perform → Outperform
Nov-17-21 Resumed
Guggenheim
Neutral
Oct-07-21 Initiated
Jefferies
Hold
$32
Mar-31-21 Initiated
Credit Suisse
Outperform
$55
Feb-25-21 Downgrade
SVB Leerink
Outperform → Mkt Perform
$41
Feb-08-21 Resumed
H.C. Wainwright
Buy
$57
Jan-25-21 Downgrade
Citigroup
Buy → Neutral
$50 → $53
Sep-29-20 Resumed
JP Morgan
Neutral
$48
Aug-06-20 Initiated
SVB Leerink
Outperform
$45
Jan-10-20 Initiated
Wolfe Research
Outperform
$61
Dec-09-19 Initiated
JP Morgan
Neutral
Nov-25-19 Initiated
H.C. Wainwright
Buy
$65
Show Previous Ratings
Sep-19-24 12:08PM
Sep-18-24 06:00AM
Sep-03-24 04:30PM
Aug-22-24 06:30AM
Aug-01-24 04:10PM
04:05PM
Loading…
04:05PM
Jul-30-24 06:30AM
Jul-25-24 04:30PM
Jul-22-24 06:00AM
Jul-11-24 06:30AM
Jun-17-24 06:00AM
Jun-10-24 06:00AM
May-28-24 06:30AM
May-19-24 09:00PM
May-16-24 04:20PM
04:05PM
Loading…
May-02-24 04:05PM
Apr-30-24 06:00AM
Apr-11-24 06:00AM
Apr-10-24 09:35AM
Apr-08-24 06:00AM
Mar-28-24 06:00AM
Mar-27-24 06:00AM
Mar-22-24 12:00PM
Mar-11-24 12:44PM
Mar-09-24 01:09PM
Mar-07-24 06:39AM
(FierceBiotech.com) -6.46%
Mar-06-24 10:53PM
04:09PM
Mar-05-24 04:30PM
Feb-28-24 10:00AM
06:00AM
Loading…
Feb-27-24 06:00AM
Feb-14-24 06:00AM
Feb-09-24 08:00AM
Feb-08-24 06:00AM
Jan-31-24 06:00AM
Jan-11-24 12:00PM
Jan-04-24 06:15AM
06:00AM
Dec-26-23 08:00AM
Dec-15-23 08:30AM
Dec-08-23 10:11AM
Nov-30-23 08:30AM
Nov-08-23 05:33PM
Nov-07-23 04:05PM
Nov-01-23 08:30AM
Oct-17-23 08:30AM
Oct-16-23 04:30PM
Aug-10-23 04:05PM
Aug-01-23 08:30AM
Jul-19-23 08:30AM
Jul-03-23 08:30AM
Jun-29-23 04:05PM
Jun-26-23 08:30AM
Jun-02-23 06:41PM
Jun-01-23 08:30AM
May-18-23 08:30AM
May-08-23 04:05PM
May-01-23 08:30AM
Apr-18-23 04:05PM
Apr-17-23 08:30AM
Apr-10-23 08:30AM
Apr-03-23 08:30AM
Mar-14-23 04:30PM
Mar-07-23 04:05PM
Feb-28-23 08:30AM
Feb-21-23 08:30AM
Jan-25-23 08:30AM
Jan-19-23 07:45AM
Jan-04-23 04:15PM
Dec-21-22 07:30AM
07:30AM
Dec-19-22 07:00AM
Dec-14-22 04:15PM
Dec-09-22 08:00AM
Dec-05-22 08:30AM
Nov-29-22 08:30AM
Nov-24-22 12:20PM
Nov-22-22 09:55AM
08:30AM
Nov-21-22 12:22PM
09:55AM
09:00AM
Nov-08-22 05:45PM
04:22PM
Nov-02-22 10:00AM
Nov-01-22 10:01AM
Oct-31-22 04:42PM
Oct-21-22 01:35PM
Oct-20-22 01:36PM
11:48AM
08:30AM
Oct-19-22 11:08AM
08:38AM
07:29AM
06:07AM
06:00AM
Oct-18-22 08:30AM
Oct-13-22 07:00AM
Oct-07-22 04:15PM
Oct-04-22 08:30AM
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Galbraith Kenneth Chair & CEO Jan 05 '24 Option Exercise 0.00 47,666 0 47,666 Jan 08 06:23 PM Galbraith Kenneth Chair & CEO Jan 05 '24 Sale 10.65 18,198 193,849 29,468 Jan 08 06:23 PM Galbraith Kenneth Chair & CEO Jan 08 '24 Sale 11.22 5,706 63,996 23,762 Jan 08 06:23 PM Astle Christopher SVP & Chief Financial Officer Jan 05 '24 Option Exercise 0.00 10,500 0 12,497 Jan 08 06:14 PM Astle Christopher SVP & Chief Financial Officer Jan 05 '24 Sale 10.65 4,563 48,606 7,934 Jan 08 06:14 PM Astle Christopher SVP & Chief Financial Officer Jan 08 '24 Sale 11.22 1,431 16,050 6,503 Jan 08 06:14 PM Moore Paul Andrew Chief Scientific Officer Jan 05 '24 Option Exercise 0.00 17,166 0 17,166 Jan 08 06:01 PM Moore Paul Andrew Chief Scientific Officer Jan 05 '24 Sale 10.65 7,460 79,465 9,706 Jan 08 06:01 PM Moore Paul Andrew Chief Scientific Officer Jan 08 '24 Sale 11.22 2,339 26,233 7,367 Jan 08 06:01 PM Astle Christopher SVP & Chief Financial Officer Dec 11 '23 Option Exercise 0.00 1,550 0 2,883 Dec 11 08:00 PM Astle Christopher SVP & Chief Financial Officer Dec 11 '23 Sale 9.13 886 8,089 1,997 Dec 11 08:00 PM
Index RUT
P/E 21.82
EPS (ttm) 0.29
Insider Own 17.16%
Shs Outstand 54.53M
Perf Week 0.00%
Market Cap 340.81M
Forward P/E -
EPS next Y -1.81
Insider Trans -0.14%
Shs Float 45.17M
Perf Month -9.02%
Income 9.02M
PEG -
EPS next Q -0.49
Inst Own 68.65%
Short Float 8.92%
Perf Quarter -22.74%
Sales 143.77M
P/S 2.37
EPS this Y -147.12%
Inst Trans 0.49%
Short Ratio 9.23
Perf Half Y -33.51%
Book/sh 6.16
P/B 1.02
EPS next Y -29.15%
ROA 2.40%
Short Interest 4.03M
Perf Year -18.78%
Cash/sh 6.80
P/C 0.92
EPS next 5Y -
ROE 3.38%
52W Range 5.97 - 11.72
Perf YTD -25.95%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI 2.40%
52W High -46.67%
Beta 0.91
Dividend TTM -
Quick Ratio 9.51
Sales past 5Y 355.29%
Gross Margin 96.61%
52W Low 4.69%
ATR (14) 0.29
Dividend Ex-Date -
Current Ratio 9.51
EPS Y/Y TTM -86.70%
Oper. Margin -4.63%
RSI (14) 38.39
Volatility 3.96% 4.01%
Employees 162
Debt/Eq 0.14
Sales Y/Y TTM -26.22%
Profit Margin 6.28%
Recom 1.33
Target Price 17.62
Option/Short Yes / Yes
LT Debt/Eq 0.12
EPS Q/Q 65.57%
Payout 0.00%
Rel Volume 4.27
Prev Close 6.32
Sales Surprise 210.88%
EPS Surprise 56.00%
Sales Q/Q 509.48%
Earnings Aug 06 AMC
Avg Volume 436.18K
Price 6.25
SMA20 -2.09%
SMA50 -15.32%
SMA200 -22.78%
Trades
Volume 1,860,989
Change -1.11%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-26-24 Initiated
Guggenheim
Buy
$22
Mar-19-24 Initiated
H.C. Wainwright
Buy
$30
Mar-07-24 Initiated
Citigroup
Buy
$16
Jan-02-24 Upgrade
Wells Fargo
Equal Weight → Overweight
$14
May-10-23 Initiated
Truist
Buy
$18
Mar-10-23 Initiated
Oppenheimer
Outperform
$14
Oct-07-21 Upgrade
Robert W. Baird
Neutral → Outperform
$6 → $9
Feb-26-21 Downgrade
Robert W. Baird
Outperform → Neutral
$18 → $6
Feb-03-21 Downgrade
Wedbush
Outperform → Neutral
$6
Feb-03-21 Downgrade
BTIG Research
Buy → Neutral
Dec-24-20 Downgrade
Cantor Fitzgerald
Overweight → Neutral
$15 → $10
Dec-23-20 Downgrade
Raymond James
Outperform → Mkt Perform
Nov-11-20 Downgrade
Oppenheimer
Outperform → Perform
Nov-10-20 Downgrade
Wells Fargo
Overweight → Equal Weight
$10
Nov-10-20 Downgrade
Raymond James
Strong Buy → Outperform
$28 → $17
Mar-19-20 Initiated
The Benchmark Company
Buy
$18
Feb-06-20 Initiated
Oppenheimer
Outperform
Nov-15-18 Upgrade
Raymond James
Outperform → Strong Buy
Sep-10-18 Resumed
BTIG Research
Buy
$32
Sep-10-18 Downgrade
Morgan Stanley
Overweight → Equal-Weight
Show Previous Ratings
Sep-16-24 07:00AM
Sep-05-24 08:00AM
Aug-29-24 04:01PM
07:00AM
Aug-07-24 07:00AM
05:15PM
Loading…
Aug-06-24 05:15PM
04:11PM
(Associated Press Finance)
04:01PM
Jul-30-24 07:00AM
Jul-23-24 04:01PM
Jul-09-24 04:01PM
Jun-13-24 04:01PM
07:00AM
May-16-24 07:00AM
May-14-24 08:16AM
(Thomson Reuters StreetEvents)
06:27AM
Loading…
06:27AM
03:03AM
May-13-24 08:56PM
05:10PM
04:09PM
(Associated Press Finance)
04:01PM
May-08-24 06:00AM
May-06-24 07:00AM
Apr-22-24 04:30PM
Apr-16-24 07:00AM
Mar-30-24 03:00AM
Mar-26-24 04:01PM
Mar-13-24 07:00AM
Mar-09-24 01:09PM
Feb-29-24 11:09AM
(Thomson Reuters StreetEvents) -7.25%
09:54AM
Loading…
09:54AM
Feb-28-24 04:41PM
04:32PM
(Associated Press Finance)
04:01PM
Feb-26-24 07:00AM
Feb-21-24 07:00AM
Feb-20-24 07:00AM
Feb-07-24 07:00AM
Jan-11-24 10:09PM
Jan-04-24 10:45PM
04:14PM
Jan-03-24 11:15AM
07:00AM
Jan-02-24 04:07PM
(Investor's Business Daily) +6.64%
01:51PM
10:46AM
07:36AM
07:14AM
07:14AM
07:09AM
07:00AM
Dec-17-23 12:03PM
Dec-08-23 10:13AM
Dec-07-23 06:10AM
(Pharmaceutical Business Review)
Dec-06-23 07:00AM
Nov-07-23 10:16AM
Nov-06-23 05:22PM
04:17PM
(Associated Press Finance)
04:01PM
Oct-30-23 07:00AM
Sep-25-23 07:00AM
Sep-07-23 04:01PM
Aug-30-23 07:00AM
Aug-22-23 08:14AM
Aug-08-23 04:01PM
Aug-07-23 08:00AM
Aug-03-23 08:25AM
07:17AM
(Associated Press Finance)
07:00AM
Aug-02-23 07:00AM
Jul-27-23 07:00AM
Jul-14-23 05:40AM
Jul-11-23 08:53PM
04:01PM
Jul-10-23 08:00AM
Jun-21-23 04:49AM
Jun-15-23 06:30AM
Jun-01-23 07:52PM
07:00AM
May-25-23 12:29PM
May-18-23 06:00AM
May-09-23 08:35AM
07:37AM
07:00AM
06:55AM
May-05-23 06:08AM
May-03-23 10:25PM
May-02-23 04:30PM
07:00AM
Apr-08-23 09:12AM
Mar-28-23 07:00AM
Mar-12-23 08:04AM
Mar-08-23 03:03AM
(Thomson Reuters StreetEvents) +10.76%
Mar-07-23 08:25AM
07:00AM
Mar-06-23 07:00AM
Feb-28-23 07:00AM
Feb-13-23 08:00AM
Feb-10-23 06:23AM
Feb-09-23 07:00AM
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Swartz Robin Chief Operating Officer Apr 02 '24 Sale 9.88 1,357 13,407 117,004 Apr 03 04:13 PM Sandrock Alfred President and CEO Apr 02 '24 Sale 9.86 12,115 119,454 322,839 Apr 03 04:10 PM Swartz Robin Chief Operating Officer Feb 21 '24 Sale 7.45 3,966 29,547 118,361 Feb 22 04:36 PM Sandrock Alfred President and CEO Feb 21 '24 Sale 7.46 13,033 97,226 334,954 Feb 22 04:34 PM PFREUNDSCHUH PETER P. Chief Financial Officer Feb 21 '24 Sale 7.46 3,764 28,079 175,669 Feb 22 04:32 PM Carter Todd Alfred Chief Scientific Officer Feb 21 '24 Sale 7.47 3,365 25,137 87,627 Feb 22 04:30 PM Carter Todd Alfred Chief Scientific Officer Feb 20 '24 Sale 7.68 602 4,623 90,992 Feb 22 04:30 PM Swartz Robin Chief Operating Officer Jan 17 '24 Sale 7.15 2,543 18,182 72,327 Jan 19 04:34 PM Carter Todd Alfred Chief Scientific Officer Jan 17 '24 Sale 7.18 1,266 9,090 53,094 Jan 19 04:32 PM PFREUNDSCHUH PETER P. Chief Financial Officer Oct 03 '23 Sale 6.99 13,567 94,833 149,433 Oct 05 04:41 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite